187 related articles for article (PubMed ID: 33449175)
1. Identifying response in colorectal liver metastases treated with bevacizumab: development of RECIST by combining contrast-enhanced and diffusion-weighted MRI.
Liu LH; Zhou GF; Lv H; Wang ZC; Rao SX; Zeng MS
Eur Radiol; 2021 Aug; 31(8):5640-5649. PubMed ID: 33449175
[TBL] [Abstract][Full Text] [Related]
2. Prediction of Therapeutic Effect to Treatment in Patients with Colorectal Liver Metastases Using Functional Magnetic Resonance Imaging and RECIST Criteria: A Pilot Study in Comparison between Bevacizumab-Containing Chemotherapy and Standard Chemotherapy.
Zhu HB; Xu D; Zhang XY; Li XT; Xing BC; Sun YS
Ann Surg Oncol; 2022 Jun; 29(6):3938-3949. PubMed ID: 35013857
[TBL] [Abstract][Full Text] [Related]
3. Equivalent cross-relaxation rate imaging and diffusion weighted imaging for early prediction of response to bevacizumab-containing treatment in colorectal liver metastases-preliminary study.
Matsushima S; Sato T; Nishiofuku H; Sato Y; Murata S; Kinosada Y; Era S; Inaba Y
Clin Imaging; 2017; 41():1-6. PubMed ID: 27721090
[TBL] [Abstract][Full Text] [Related]
4. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging.
Anzidei M; Napoli A; Zaccagna F; Cartocci G; Saba L; Menichini G; Cavallo Marincola B; Marotta E; Di Mare L; Catalano C; Passariello R
J Comput Assist Tomogr; 2011; 35(6):690-6. PubMed ID: 22082538
[TBL] [Abstract][Full Text] [Related]
5. Quantitative evaluation of liver metastases density on computed tomography: A new tool to evaluate early response to bevacizumab-containing chemotherapy.
Mazard T; Assenat E; Dupuy M; Mollevi C; René A; Adenis A; Chauffert B; Boucher E; Francois E; Pierga JY; Ducreux M; Ychou M; Gallix B
Dig Liver Dis; 2019 Aug; 51(8):1185-1191. PubMed ID: 31085108
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of pretreatment diffusion-weighted magnetic resonance imaging for outcome prediction of colorectal cancer liver metastases undergoing 90Y-microsphere radioembolization.
Schmeel FC; Simon B; Luetkens JA; Träber F; Meyer C; Schmeel LC; Sabet A; Ezziddin S; Schild HH; Hadizadeh DR
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1531-1541. PubMed ID: 28317063
[TBL] [Abstract][Full Text] [Related]
7. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases.
Chun YS; Vauthey JN; Boonsirikamchai P; Maru DM; Kopetz S; Palavecino M; Curley SA; Abdalla EK; Kaur H; Charnsangavej C; Loyer EM
JAMA; 2009 Dec; 302(21):2338-44. PubMed ID: 19952320
[TBL] [Abstract][Full Text] [Related]
8. Texture features of colorectal liver metastases on pretreatment contrast-enhanced CT may predict response and prognosis in patients treated with bevacizumab-containing chemotherapy: a pilot study including comparison with standard chemotherapy.
Ravanelli M; Agazzi GM; Tononcelli E; Roca E; Cabassa P; Baiocchi G; Berruti A; Maroldi R; Farina D
Radiol Med; 2019 Sep; 124(9):877-886. PubMed ID: 31172448
[TBL] [Abstract][Full Text] [Related]
9. Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Dohan A; Gallix B; Guiu B; Le Malicot K; Reinhold C; Soyer P; Bennouna J; Ghiringhelli F; Barbier E; Boige V; Taieb J; Bouché O; François E; Phelip JM; Borel C; Faroux R; Seitz JF; Jacquot S; Ben Abdelghani M; Khemissa-Akouz F; Genet D; Jouve JL; Rinaldi Y; Desseigne F; Texereau P; Suc E; Lepage C; Aparicio T; Hoeffel C;
Gut; 2020 Mar; 69(3):531-539. PubMed ID: 31101691
[TBL] [Abstract][Full Text] [Related]
10. Intravoxel Incoherent Motion of Colon Cancer Liver Metastases for the Assessment of Response to Antiangiogenic Treatment: Results from a Pilot Study.
Öz A; Server S; Koyuncu Sökmen B; Namal E; İnan N; Balcı NC
Med Princ Pract; 2020; 29(5):429-435. PubMed ID: 31914438
[TBL] [Abstract][Full Text] [Related]
11. Diffusion-weighted and hepatobiliary phase gadoxetic acid-enhanced quantitative MR imaging for identification of complete pathologic response in colorectal liver metastases after preoperative chemotherapy.
Hosseini-Nik H; Fischer SE; Moulton CA; Karbhase G; Menezes RJ; Gallinger S; Jhaveri KS
Abdom Radiol (NY); 2016 Feb; 41(2):231-8. PubMed ID: 26867904
[TBL] [Abstract][Full Text] [Related]
12. Treatment response of colorectal cancer liver metastases to neoadjuvant or conversion therapy: a prospective multicentre follow-up study using MRI, diffusion-weighted imaging and
Uutela A; Ovissi A; Hakkarainen A; Ristimäki A; Lundbom N; Kallio R; Soveri LM; Salminen T; Ålgars A; Halonen P; Ristamäki R; Nordin A; Blanco Sequeiros R; Rinta-Kiikka I; Lantto E; Virtanen J; Pääkkö E; Liukkonen E; Saunavaara J; Ryymin P; Lammentausta E; Osterlund P; Isoniemi H;
ESMO Open; 2021 Aug; 6(4):100208. PubMed ID: 34325107
[TBL] [Abstract][Full Text] [Related]
13. Multiparametric MRI with diffusion-weighted imaging in predicting response to chemotherapy in cases of osteosarcoma and Ewing's sarcoma.
Saleh MM; Abdelrahman TM; Madney Y; Mohamed G; Shokry AM; Moustafa AF
Br J Radiol; 2020 Nov; 93(1115):20200257. PubMed ID: 32706980
[TBL] [Abstract][Full Text] [Related]
14. Response evaluation in patients with colorectal liver metastases: RECIST version 1.1 versus modified CT criteria.
Chung WS; Park MS; Shin SJ; Baek SE; Kim YE; Choi JY; Kim MJ
AJR Am J Roentgenol; 2012 Oct; 199(4):809-15. PubMed ID: 22997372
[TBL] [Abstract][Full Text] [Related]
15. Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: A post hoc analysis of the WJOG4407G phase III study.
Hosokawa A; Yamazaki K; Matsuda C; Ueda S; Kusaba H; Okamura S; Tsuda M; Tamura T; Shinozaki K; Tsushima T; Tsuda T; Shirakawa T; Yamashita H; Morita S; Hironaka S; Muro K
Medicine (Baltimore); 2020 Sep; 99(36):e22060. PubMed ID: 32899071
[TBL] [Abstract][Full Text] [Related]
16. Radiologic and pathologic response to neoadjuvant chemotherapy predicts survival in patients undergoing the liver-first approach for synchronous colorectal liver metastases.
Berardi G; De Man M; Laurent S; Smeets P; Tomassini F; Ariotti R; Hoorens A; van Dorpe J; Varin O; Geboes K; Troisi RI
Eur J Surg Oncol; 2018 Jul; 44(7):1069-1077. PubMed ID: 29615295
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of ADC measurements in predicting overall survival in patients undergoing
Alis D; Durmaz ESM; Gulsen F; Bas A; Kabasakal L; Sager S; Numan F
Clin Imaging; 2019; 57():124-130. PubMed ID: 31220677
[TBL] [Abstract][Full Text] [Related]
18. Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab.
Mazard T; Boonsirikamchai P; Overman MJ; Asran MA; Choi H; Herron D; Eng C; Maru DM; Ychou M; Vauthey JN; Loyer EM; Kopetz S
Gut; 2018 Jun; 67(6):1095-1102. PubMed ID: 29084828
[TBL] [Abstract][Full Text] [Related]
19. Predicting Treatment Response of Colorectal Cancer Liver Metastases to Conventional Lipiodol-Based Transarterial Chemoembolization Using Diffusion-Weighted MR Imaging: Value of Pretreatment Apparent Diffusion Coefficients (ADC) and ADC Changes Under Therapy.
Lahrsow M; Albrecht MH; Bickford MW; Vogl TJ
Cardiovasc Intervent Radiol; 2017 Jun; 40(6):852-859. PubMed ID: 28357571
[TBL] [Abstract][Full Text] [Related]
20. Early evaluation of liver metastasis using spectral CT to predict outcome in patients with colorectal cancer treated with FOLFOXIRI and bevacizumab.
Li S; Yuan L; Yue M; Xu Y; Liu S; Wang F; Liu X; Wang F; Deng J; Sun Q; Liu X; Xue C; Lu T; Zhang W; Zhou J
Cancer Imaging; 2023 Mar; 23(1):30. PubMed ID: 36964617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
